About Adagene Inc.
https://www.adagene.comAdagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
CEO
Peter Luo
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 9, 2021
Method of going public IPO
Full time employees 138
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $5
Target Low $5
Target Median $5
Target Consensus $5
Institutional Ownership
WUXI APPTEC CO., LTD.
Shares:3.98M
Value:$7.17M
GENERAL ATLANTIC, L.P.
Shares:3.78M
Value:$6.81M
SC CHINA HOLDING LTD
Shares:1.34M
Value:$2.42M
Summary
% Of Shares Owned 25.74%
Total Number Of Holders 19
Showing Top 3 of 19
Market Cap $62.21 M
52w High $3.16
52w Low $1.30
P/E -2.81
Volume 61.28K
Outstanding Shares 37.71M
About Adagene Inc.
https://www.adagene.comAdagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 ▼ | $15.43M ▼ | $-13.51M ▲ | 0% ▲ | $-0.36 ▲ | $-12.89M ▲ |
| Q4-2024 | $103.2K ▲ | $26.89M ▲ | $-24.92M ▼ | -24.14K% ▼ | $-0.71 ▼ | $-22.7M ▼ |
| Q2-2024 | $0 | $9.16M ▼ | $-8.51M | 0% | $-0.24 | $-8.96M |
| Q1-2024 | $0 ▼ | $9.28M ▲ | $-8.51M ▼ | 0% ▲ | $-0.24 ▼ | $-8.96M ▲ |
| Q4-2023 | $407.87K | $9.05M | $-7.42M | -1.82K% | $-0.21 | $-9.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $62.83M ▼ | $66.52M ▼ | $28.61M ▼ | $37.91M ▼ |
| Q4-2024 | $85.19M ▼ | $89.27M ▼ | $38.74M ▼ | $50.52M ▼ |
| Q2-2024 | $95.67M | $100.78M | $44.19M | $56.59M |
| Q1-2024 | $95.67M ▼ | $100.78M ▼ | $44.19M ▼ | $56.59M ▼ |
| Q4-2023 | $109.93M | $115.73M | $45.17M | $70.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-13.51M ▲ | $-11.16M ▲ | $242.2K ▼ | $-11.63M ▼ | $-22.37M ▼ | $-11.16M ▲ |
| Q4-2024 | $-24.92M ▼ | $-23.01M ▼ | $662.88K ▲ | $5.21M ▲ | $-10.48M ▼ | $-23.04M ▼ |
| Q2-2024 | $-8.51M | $-6.69M | $223.62K | $-1.44M ▼ | $-7.13M | $-6.69M |
| Q1-2024 | $-8.51M ▼ | $-6.69M ▼ | $223.62K ▲ | $-718.03K ▼ | $-7.13M ▼ | $-6.69M ▼ |
| Q4-2023 | $-7.42M | $0 | $0 | $0 | $0 | $0 |
CEO
Peter Luo
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 9, 2021
Method of going public IPO
Full time employees 138
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $5
Target Low $5
Target Median $5
Target Consensus $5
Institutional Ownership
WUXI APPTEC CO., LTD.
Shares:3.98M
Value:$7.17M
GENERAL ATLANTIC, L.P.
Shares:3.78M
Value:$6.81M
SC CHINA HOLDING LTD
Shares:1.34M
Value:$2.42M
Summary
% Of Shares Owned 25.74%
Total Number Of Holders 19
Showing Top 3 of 19